Pharmacyclics has entered into a global partnership with Johnson & Johnson’s Janssen Biotech unit for its mid-stage haematological cancer programme, PCI-32765. The collaboration, potentially worth up to US$975 M, will cover oncology and other indications, excluding inflammation and immune-mediated conditions. Each company will lead development for specific indications, with Pharmacyclics assuming 40% of development costs and Janssen Biotech the remaining 60%. If approved, the two companies will co-commercialise the product and share profits and losses equally.